A Comparative Study on Anticancer Effects of the Alhagi maurorum and Amygdalus haussknechtii Extracts Alone and in Combination with Docetaxel on 4T1 Breast Cancer Cells by Bahamin, Nayereh et al.
Research Article
A Comparative Study on Anticancer Effects of the Alhagi
maurorum and Amygdalus haussknechtii Extracts Alone
and in Combination with Docetaxel on 4T1 Breast Cancer Cells
Nayereh Bahamin,1 Shahin Ahmadian ,1 Mahmoud Rafieian-Kopaei ,2
Gholamreza Mobini,3 Mahshid Shafiezadeh,1 and Amin Soltani2
1Department of Biochemistry, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran
2Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
3Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
Correspondence should be addressed to Shahin Ahmadian; sh.ahmadian@ut.ac.ir and Mahmoud Rafieian-Kopaei;
rafieian@yahoo.com
Received 11 January 2021; Accepted 19 May 2021; Published 15 June 2021
Academic Editor: Juntra Karbwang
Copyright © 2021 Nayereh Bahamin et al. *is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Medicinal plants have long been studied due to their anticancer effects and use of them is commonly increased as a com-
plementary and alternative medicine (CAM therapies) among patients with cancer. In this study, Alhagi maurorum (A.m) and
Amygdalus haussknechtii (A.h) extracts were evaluated for their effects on inhibiting the growth of 4T1 breast cancer cells. Based
on MTTassay results, the IC50s of A.m and A.h extracts were 57 µg/ml and 85 µg/ml, respectively. *en the cell migration, gene
expression, and degree of apoptosis after 48 hours in each treated group with A.m and A.h extracts alone or in combination with
docetaxel (DTX) on 4T1 cells were evaluated. A.m had a synergistic behavior with DTX (CI< 1). A.h reduced DTX IC50 but
presented CI> 1. Cell migration assay showed that each extract alone or in combination with DTX prevented the migration of 4T1
cells. *e Ao/EB staining and flowcytometry results confirmed that, in combination therapy, A.m+DTX and A.h +DTX induced
apoptosis close to the level of DTX. Real-time PCR analysis showed that A.m+DTX (IC50 + IC25) downregulated the mRNA
expression of HIF-1α and FZD7. A.m+DTX (IC50 + IC10) group decreased the expression of HIF-1α. Moreover, in A.h +DTX
(IC50 + IC25) group, β-Catenin and FZD7 were downregulated and upregulated, respectively. Generally, our findings suggest that
the combination of A.m and DTX possesses synergistic antitumor effects on 4T1 cells, which may be a valuable choice for CAM
therapies. A.h has an acceptable antitumor activity but not in combination with DTX.
1. Introduction
Despite enormous medicinal developments in recent de-
cades, a large number of people suffer from cancer. Based on
the statistics adapted from the American Cancer Society and
the International Union Against Cancer, 27 million diag-
noses and 17 million deaths will occur by 2030 worldwide
[1]. Breast cancer is the first deadly cancer among women
[2]. Triple-negative breast cancer (TNBC) is one of the breast
cancer subtypes that cannot be controlled with standard-of-
care therapy [3].
Chemotherapy drugs usually have a lot of side effects and
limitations due to nonspecificity, and resistance to some of
them is usually observed sometime after using the drug
[4–6]. Docetaxel (Taxotere®) (DTX) is a semisynthetic de-rivative of paclitaxel which was found to be more effective
because of being soluble in water. DTX is used as a treatment
remedy in patients suffering from breast, ovarian, and/or
metastatic cancers [7]. Today, studies have shown that many
plants recommended in traditional medicine against cancer
have positive effects on cell lines in laboratory or animal
studies and they are great sources for discovering new drugs.
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*e concurrent use of multiple medications can apply
treatment from multiple paths to one or more targets.
Combination therapy or synergistic therapy has several
benefits such as increasing treatment efficacy, reducing dose
and toxicity, and minimizing drug resistance. Hence, drug
combinations have been widely used, especially in most
dreadful diseases, such as cancer, and infectious diseases,
including acquired immunodeficiency syndrome (AIDS)
[8]. Also, combining medicinal plants with chemothera-
peutics, including DTX, can be useful in reducing the
toxicity and side effects of chemotherapy [6, 9].
One of the pathways which is tightly associated with
cancer and is activated in more than 50% of breast cancers is
Wnt signaling [10]. *is pathway consists of β-Catenin
dependent and independent signaling groups [11]. In many
studies, it has been shown that a number of medicinal plants
or their compounds are effective on the activity of the Wnt
path [12–14]. *e use of complementary and alternative
medicines (CAM) in cancer patients is growing, and
pharmacokinetic interactions between CAM and chemo-
therapeutics that might lead to either increased or decreased
plasma levels of anticancer drugs should be investigated [15].
Before starting the main study, we found the effective
plants in the treatment of various types of cancer from
literature to find the most effective and desired plants and
then selected 20 of the available types. *en we tested their
inhibitory effect on the growth of 4T1 breast cancer cells,
among which A. m and A. h had the most favorable effect,
respectively (data are available in the supplementary file).
A. maurorum is a plant from the Fabiaceae family which
has been widely used in traditional medicine in the treat-
ment of various diseases, and scientists have recently studied
its anticancer effect on some cell lines [16–18].*is plant has
many biological properties such as antioxidant, antimicro-
bial, cytotoxic, anti-inflammatory, antiproliferative prop-
erties [19]. Previous studies revealed the presence of
flavonoids, glycosides, saponins, tannins, alkaloids, steroids,
and anthraquinone in the A. m extract [20, 21].
Also Lupeol as an active fraction was detected by nuclear
magnetic resonance in A. m inducing apoptosis in human
breast cancer cells [22].
A. haussknechtii is one of the amygdalus species which is
grown in a few provinces of Iran, including Chaharmahal
and Bakhtiari. During local research, we found that indig-
enous people, in addition to using the fruit of this plant, use
its leaves to treat some diseases. *erefore, we decided to
examine it in this study. In a study, the phenolic content of
leaves of several types of wild almonds was examined and it
was found that the highest phenolic content (gallic acid) was
related to A. h [23]. Because of the benefits mentioned above
for combination therapy, the aim of the current study was to
evaluate the effects of A. m and A. h extracts alone and in
combination with docetaxel on 4T1 breast cancer cells.
2. Experimental
2.1. Cell Culture. 4T1 cells were obtained from the Pasteur
Institute (Tehran, Iran). *e 4T1 cells were cultured in
RPMI1640 medium containing 10% Fetal Bovine Serum
(FBS) and 1% Penicillin-Streptomycin and were kept in a
humidified incubator at 37°C with 5% CO2.
FBS (Gibco, Auckland, New Zealand), RPMI1640 me-
dium, Penicillin-Streptomycin, MTT ([3-(4,5-dimethylthi-
azol-2-yl)-2,4-diphenyl tetrazolium bromide]) (Sigma, St.
Louis, MO, USA), DMSO (dimethyl sulphoxide) (Merck,
Hohenbrunn, Germany), and PBS (Sigma-Aldrich, Stein-
hem, Germany) were used in cell culture and cytotoxic
activity evaluation.
2.2. Medicinal Plants and DTX. A. h leaves were collected
from Chaharmahal and Bakhtiari province and aerial parts
of A. m were purchased from authentic local store and
confirmed by a botanist at the Medical Plants Research
Center, Shahrekord University of Medical Sciences, Shah-
rekord, Iran.*e plants were dried in shadow and grounded.
DTX (20mg) manufactured by NanoAlvand Co. (Teh-
ran, Iran) was purchased from a drugstore.
2.3. Plant Extraction. Ethanol (Merck, Hohenbrunn, Ger-
many) was used for plants extraction. Hydroalcoholic ex-
tract (ethanol 70%) was prepared and maceration method
was used for plants extraction. To this purpose, the dried
powdered plants were soaked in a hydroalcoholic solution
for 48 hours, and, after passing through the filter paper, they
were concentrated with a rotarymachine and the solvent was
removed. *e concentrated extracts were dried in freeze
dryer and the resulting powders were kept at 2–8°C for
future assays. *e extract powders were dissolved in DMSO
to make the stock solutions of each sample (5mg mL−1).
Serial dilutions were made from the stock solutions to reach
final concentrations (DMSO 1%) [24].
2.4. Assessment of Cell Growth after Treatment. For quan-
tification of cell viability using MTT assay, after trypsini-
zation of 4T1 cells, they were seeded onto 96-well plates at
6×105 and incubated at 37°C. After 24 h of incubation and
when the cells had about 35% confluences, they were treated
with fresh medium containing serial dilutions of each plant
extract. *e control cells medium also contained 1% DMSO
vehicle. After 48 h of treatment, the supernatants were re-
moved and MTT solution (0.5mg mL−1) was added and
incubated for 4 h.*en, the supernatants were removed, and
DMSO was added. *e plates were then placed on a shaker
for 20 minutes.*e absorbance of each well was measured in
Stat Fax2100 microtiter plate reader at the wavelength of
570 nm. In this way, cell survival was measured in the form
of [A] samples/[A] control∗ 100, where [A] was the ab-
sorbance of test samples and control, respectively. *e dose-
viability curves were fitted by Excel software and IC50 values
were calculated. In such studies, the extracts with IC50
greater than 100 μg/mL were considered as ineffective ex-
tracts [24]. All experiments were carried out in 3 individual
plates with at least three parallel wells.
2.5. Assessment of Combined Treatment Using Median-Effect
Plot Analysis. CompuSyn software (set up by Dr. Dorothy
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Chou, ComboSyn Inc., 2005) was used for analysis of results
of the MTT assay. Briefly, dose-response curves were gen-
erated for individual drugs, and then combination indexes
(CI) were calculated for each combination. CI< 1 represents
synergy, CI� 1 shows additive effect, and CI> 1 indicates
antagonism.
2.6. Apoptosis Analysis Using Annexin V Staining.
Double-staining was done using the Annexin V and Pro-
pidium Iodide kit (BD Pharmingen™) according to the
manufacturer’s protocol in order to determine percentages
of viable, apoptotic, and necrotic cells following 48-hour
exposure to DTX, A. m and A. h extracts, and combination
of each extract with DTX. For this purpose, 4T1 cells were
seeded onto 6 well plates, and, after treatment with each of
the above items, they were trypsinized with repetitive
pipetting and washed with PBS (centrifuged at 1200 rpm for
5min). Untreated cells were used as negative controls. After
counting them, they were resuspended in 100 μl of the
binding buffer solution per 100000 cells. After adding
annexin V and PI, they were incubated for 15min in the dark
at 25°C. Annexin V-FITC binding was detected by flow
cytometer (space Partec, Germany) (Ex� 488 nm,
Em� FITC 495–519 nm, PI 535–617 nm, FL1 filter for
annexin V/FITC and FL2 filter for PI). *e data were an-
alyzed using FloMax software version 2.70 (Partec GmbH,
Münster, Germany).
2.7. Acridine Orange/Ethidium Bromide (AO/EB) Staining.
Acridine Orange/Ethidium Bromide (AO/EB) was purchased
from Sigma Chemical Company (Becton Dickinson, San, CA,
USA). *is test is done to visualize nuclear changes and apo-
ptotic body formation and observation of characteristics of
apoptosis. Cells were viewed under Zeiss fluorescence micro-
scope connected to a CCD camera. Briefly, 4T1 cells were
seeded onto 6-well plates and treated for 48hours with DTX,
A. m and A. h extracts, and combination of each extract with
DTX. *en, they were harvested and 25µl of cell suspension
(0.5×106 to 2.0×106 cells/ml) was incubated with 1µl of AO/
EB solution. Each sample was mixed just prior to microscopy.
*en, 10µl of cell suspension was placed onto a microscopic
slide, covered with a glass coverslip, and examined using a
fluorescein filter and a 40X objective.
2.8. Cell Migration Assay. *e 4T1 cells were seeded onto 12-
well culture plates to form a monolayer, and then identical
straight strip scratches were created using sterile yellow tips.
After that, the cells were washed with PBS and incubated with
RPMI containing 2% FBS (this FBS concentration allows cell
survival with no cell proliferation) and different concentrations
of hydroalcoholic extract of A. m (IC10), A. h (IC10), and DTX
(IC10) and the combination groups of each of these two extracts
with DTX (IC10 of DTX with IC10 extracts). After 48h of
incubation, the 4T1 cells were washed with PBS and photo-
graphed using a camera connected to an inverted microscope
(Nikon, Eclipse TS100) at 10× magnifications. Relative width of
scratch was obtained using ImageJ software.
2.9. Quantitative Real-Time PCR. Total RNA was extracted
from 4T1 cells treated with each of A. m, A. h, and DTX as well
as A. m and A. h combined with DTX (IC50 of each of extracts
with IC10 and IC25 of DTX) for 48h using the total RNA
extraction kit (Pars Tous, Iran). *e quantity of the isolated
RNA was characterized by NanoDrop ND-1000 (NanoDrop
Technologies,Wilmington, DE).*e complementary DNAwas
synthesized by cDNA synthesis kit (Pars Tous, Iran). Primers for
genes, frizzled7 (FZD7), hypoxia inducible factor 1α (HIF-1α),
vascular endothelial growth factor-a (VEGF-a), beta-Catenin
(β-Catenin), and the housekeeping gene glyceraldehydes 3-
phosphate dehydrogenase (GAPDH) were designed using
Oligo7 software (Table 1). SYBR Premix Ex TaqTM II (Tli RNase
H Plus) (Takara BIO, Inc., Otsu City, Shiga, Japan) was used.
Real-time PCR amplifications were run using a Rotor-Gene
3000 (Corbett Research, Sydney, Australia). Normalization of
the expression levels of the target genes to the housekeeping
gene GAPDH was done using REST software (QIAGEN
GmbH, 2009, v2.0.13). Finally, the fold change in expression
level of each mRNA was quantified based on Pfaffl method.
2.10. Statistical Analysis. Experimental data were expressed
by mean± standard deviation of three independent assays.
*e results of gene expression were shown as mean-
± standard error of the mean.
Statistical significance was calculated using one-way
ANOVA by GraphPad Prism software. Statistically different
values were defined to be significant at ∗P< 0.05, ∗∗P<
0.01, ∗∗∗P< 0.001, and ∗∗∗∗P< 0.0001.
3. Results
3.1. Effects ofA.mandA.h onViability of 4T1Cells. MTTassay
showed that treating 4T1 cells with different concentrations of
each of the mentioned medicinal plants caused various re-
ductions in cell viability. *e IC50 values were about 57 and
85µg/ml for A. m and A. h, respectively. Figure 1 shows the
effect of A.m andA. h extracts on viability of 4T1 cell line. In the
following, the meanings of the cases referred to by IC10, IC25,
and IC50 are the following numbers; for A. m: IC10� 32µg/ml,
IC25� 40µg/ml, and IC50� 57µg/ml; for A. h: IC10�10µg/
ml, IC25� 33µg/ml, and IC50� 85µg/ml; and for DTX:
IC10� 0.4µM, IC25� 3.5µM, and IC50�11µM.
3.2. CombinedEffect ofA.mandA.hExtractswithDTXon4T1
Cells. A. m and A. h extracts both showed IC50<100µg ml−1
in 4T1 cells. *is represents very good potential of these plants
to inhibit the growth of this cancer cell line. Since some me-
dicinal plants have been shown to have synergistic effects in
combination with chemical drugs or they have been able to
reduce their side effects or drug resistance [9, 25, 26], we in-
vestigated the combination of these two plants withDTX,which
is used to treat breast cancer. First, usingMTTassay, the IC50 of
DTX was calculated to be about 11µM (Figure 1(c)). *en, by
selecting some concentrations lower and higher than IC50 for
each extract orDTX,MTTassaywas done again in combination
mode. *e combination index (CI) was calculated by entering
doses and their effects in CompuSyn software.
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According to the calculations performed by software, it was
found that A. m at doses below 100µg/ml in combination with
DTX had a CI<1, indicating synergy. *e results of isobolo-
gram analysis (Figure 2(a)) were in agreement with fraction
affected (FA) versus CI; in this way A. m at doses below 100µg/
ml in combination with DTX was below the line of additive
effects, demonstrating the synergistic antiproliferative effect of
DTX+A. m combination (Figure 2(c)). A. m concentrations
above 100µg/ml had antagonistic effects. *e results of com-
bining A. h extract with DTX showed that most of the points
were above the additive effect line and had antagonistic effects.
*ese results of isobologram analyses and FA versus CI are
shown in Figures 2(b) and 2(d), respectively. Table 2 shows the
doses used for extracts and DTX, as well as the values of CI
obtained from the software analysis for each combination.
In other experiments, we investigated the effects of the
increased concentrations of A. m extract on a range of DTX
concentrations (15, 31, 57, 62, and 125 µg/ml of A. m extract
and 31, 62, 84, and 125 µg/ml of A. h extract each time in a
separate trial). Results showed that A. m significantly re-
duced the IC50 values of DTX, but A. h showed less effect
(Figures 2(e) and 2(f )).
3.3. Effects of A.m and A.h Extracts on Migration of 4T1 Cells.
As shown in Figure 3, in treated groups, the scratch closure was
delayed after 24 hours. At time 0, the relative width of injury line
(scratch width) in the untreated group and in the other treated
groups is considered 100%. In the untreated group, after 12 and
24 hours, significant scratch closure was observed due to the
migration of 4T1 cells. In the group treated with A. m (IC10),
the relative width of the scratch did not change much after 24
hours. A. h (IC10) yielded a relative width of ∼92.68% andDTX
(IC10) had a relative width of about 90.13% after 24 h. In the
group treated with A. h+DTX (IC10 of both of them) and
A. m+DTX (IC10 of both of them), the scratch remained
approximately the same after 24 hours with relative width of
Table 1: Name of genes, accession numbers, and nucleotide sequences of the primers used for real-time PCR.
Gene Accession no. Forward primer (5′-3′) Reverse primer (3′-5′) Size of product
HIf-1α XM_017314961.1 CTGGATGCCGGTGGTCTA ACCCCATGTATTTGTTCACGTT 148
FZD7 NM_008057.3 ATATCGCCTACAACCAGACCAT AGGAACGGCACGGAGGAA 192
VEGFa NM_001025257.3 GAGCAGAAGTCCCATGAAGTGA CACAGGACGGCTTGAAGATGT 133
β-Catenin NM_007614.3 ATGCGTTCTCCTCAGATGGTGTC CAGAATCCACTGGTGAACCAAGC 187




















































































Figure 1: Effect of DTX and A.m and A.h extracts on viability of 4T1 cell line. (a) 4T1 cells treated with varying doses of A.m for 48 h. (b) 4T1
cells treated with varying doses of A.h for 48 h. (c) 4T1 cells treated with varying doses of DTX for 48 h. Cell viability was determined using
MTTassay. Results are reported as a percentage of viability compared with control and are presented as mean± SD from three independent
experiments. Significance was set at ∗P< 0.05, ∗∗P< 0.01, ∗∗∗P< 0.001 and ∗∗∗∗P< 0.0001.
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99.48% and 96.14%, respectively, but the cells were a little
deformed and some of the cell debris was seen in the gap.*ese
results indicate that the used treatments can significantly im-
pede the migration of 4T1 cells. In the untreated group, the gap
was significantly closed, but, in other groups, except for DTX
and A. h, which slightly reduced the scratch width, there was no
significant difference across the scratch after 24 hours.
3.4. Apoptosis Analysis after Treatment with DTX, A.m, and
A.h Extracts Alone or in Combination with DTX in 4T1 Cell
Line. In the case of A. m, IC50 of this extract significantly
induced apoptosis (45.12%) compared to control group
(13.53%). But A. m+DTX (IC50+IC25) and A. m+DTX
(IC50+ IC10) groups increased apoptosis (68.92% and 65.5%,
respectively) to a level close to DTX (74.85%) and this effect was
significantly higher than that of A. m alone. A. m+DTX
(IC10+ IC10) group (46.2% apoptosis) had the least necrosis.
A. h+DTX (IC10+ IC10) (40.8%) increased the extent of
apoptosis close to the amount of DTX (41.6%). A. h+DTX
(IC50+ IC10) group (63.3%) increased apoptosis even more
than DTX alone. In all groups, apoptosis was increased sig-
nificantly compared to the control. *e obtained results are






































































































Figure 2: Combination effect of DTX and A.m or A.h extract on 4T1 cells. ((a) and (b)) Isobologram analysis represents the synergistic effect
of most of points for A.m+DTX combination. A.m concentrations > 100 µg/ml in combination mode represent antagonism. *e
combination index (CI) was calculated by CompuSyn software. Points above and below the isoeffect line reflect antagonism and synergy,
respectively. 15 data points were entered for each combination. ((c) and (d)) *e fraction affected (FA) versus CI curve: FA is defined as the
growth inhibition affected by the dose. CI< 1, CI� 1, and CI> 1 indicate synergism, additive effect (solid line), and antagonism effects,
respectively. (e) Effect of A.m extract on the IC50 value of DTX : 4T1 cells were treated with A.m+DTX at various concentrations for 48 h
and then cell viability was assessed byMTTassay. Combined treatments resulted in significant decrease in IC50 of DTX at 15, 31, 51, 62, and
125 µg/ml of A.m. (f ) Effect of A.h extract on the IC50 value of DTX: 4T1 cells were treated with A.h +DTX at multiple concentrations for 48
(h) and then cell viability was assessed by MTTassay. Combined treatments resulted in a significant decrease in IC50 of DTX at 62, 84, and,
125 µg/ml of A.h. Values are given as mean± SD of three independent experiments. ∗∗∗∗P< 0.0001, ∗∗P< 0.01 represent significant
changes in the IC50 of DTX.
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Table 2: *e doses for extracts (A.m and A.h) and DTX, as well as the values of CI obtained from the CompuSyn software analysis.
Combination of A.m+DTX Combination of A.h +DTX
Dose of A.m (µg/ml) Dose of DTX (µM) Effect CI Dose of A.h (µg/ml) Dose of DTX (µM) Effect CI
15 0.8 0.49 0.32 31 1 0.1 >100
15 20 0.57 0.78 31 10 0.27 66.84
15 100 0.98 0.03 31 100 0.93 0.19
31 4 0.52 0.73 62 0.1 0.015 >100
31 20 0.6 0.73 62 1 0.11 >100
31 100 0.98 0.08 62 10 0.32 24.74
57 0.8 0.63 0.69 62 100 0.9 0.43
57 4 0.59 0.82 84 10 0.25 >100
57 100 0.98 0.15 84 100 0.91 0.56
62 0.8 0.66 0.71 125 10 0.057 >100
62 4 0.63 0.79 125 100 0.95 0.70
62 100 0.98 0.16 250 0.1 0.82 2.07
125 0.8 0.72 1.26 250 1 0.77 2.26
125 4 0.65 1.48 250 10 0.39 10.00







































































Figure 3: Effect of DTX and A.m and A.h extracts on 4T1 cell migration. (a) Images of the cell migration assay of 4T1 cells following
incubation with DTX (IC10), A.m (IC10), A.h (IC10), DTX+A.m (IC10 + IC10), and DTX+A.h (IC10 + IC10) or without treatment, at 0, 6,
and 24 h. (b) Quantitative analysis of the scratch assay based on the width of scratch at 0 h. Relative widths at 6 and 24 h were calculated and
presented as the mean± SD from three independent experiments. Significance was set at ∗P< 0.1, ∗∗P< 0.01, ∗∗∗∗P< 0.0001. IC10 values
for A.m, A.h, and DTX were 32 µg/ml, 10 µg/ml, and 0.4 µM, respectively.
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3.5. AO/EB Staining Assay for Detection of Apoptotic Cells.
Apoptotic and necrotic cells are detectable under
fluorescence microscope based on the cell morphology and
membrane integrity. By penetrating into viable cells, AO
causes the nucleus of the cells to be seen in green with
organized structure nuclei. However, nonliving cells take up
EtBr in the absence of membrane integrity and are seen in a
range of yellow-orange-red [27]. Accordingly, cells with
early apoptosis have green nuclei with condensed or frag-
mented chromatin and have a crescent-shaped or granular
yellow-green staining. But cells with late apoptosis have
orange-to-red nuclei with condensed or fragmented chro-
matin. Necrotic cells will show increased volume and or-
ange-to-red organized structure nuclei [28].
As shown in Figure 5, the result of fluorescence microscopy
of nuclear dye stained 4T1 cells showed that, in the untreated
group (negative control), the nuclei were homogeneous and
round, and the cells were seen in green. Green and red nuclei
with condensed chromatin were observed in the groups treated
with DTX, A. m, and A. h, indicating early and late apoptosis.
In combination groups, there were more apoptosis in
groups e (IC50 A. m+ IC50 DTX) and specially f (IC50
a. A.m
b. DTX
c. A.m + DTX (IC10 + IC10)
d. A.m + DTX (IC50 + IC10)
e. A.m + DTX (IC50 + IC25)




























c. A.h + DTX (IC10 + IC10)
d. A.h + DTX (IC50 + IC10)
e. A.h + DTX (IC50 + IC25)



























Figure 4: Flow cytometric analysis of apoptotic detection. (a, b) Effect of A.m and DTX alone and in combination with each other on
induction of apoptosis of 4T1 cells. A.m+DTX (IC50 + IC25; IC50 + IC10; IC10 + IC10) combination groups had a bigger apoptotic effect
compared to A.m extract alone. (c, d) Effect of individual and combinational A.h and DTX on induction of apoptosis of 4T1 cells. All
combination groups had a bigger apoptotic effect compared to A.h extract alone, and A.h +DTX (IC50 + IC10) group had a bigger apoptotic
effect compared to both of A.h and DTX alone. IC values were as follows: for A.m : IC10� 32 µg/ml, IC25� 40 µg/ml, and IC50� 57 µg/ml;
for A.h : IC10�10 µg/ml, IC25� 33 µg/ml, and IC50� 85 µg/ml; and for DTX : IC10� 0.4 µM, IC25� 3.5 µM, and IC50�11 µM.
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A.m+ IC10DTX) and apoptotic bodies were clearly evident. In
group g (IC25 A. m+ IC25 DTX), the red color of the nuclei
and the increase of cell volume indicated necrosis. In group h
(IC10 A. m+IC10 DTX), the nuclei with orange fluorescence
showed late apoptosis. In the case of A. h extract +DTX
combination, groups j (IC50 A. h+ IC10 DTX) and l (IC10
A. h+ IC10 DTX) exhibited more apoptosis than group i (IC50
A. h+ IC50 DTX). Group k (IC25 A. h+ IC25 DTX) showed
necrosis. *ese data are consistent with the results of flow
cytometry.
3.6. Effect of DTX, A.m, and A.h Extracts and Aeir Combi-
nations on Wnt/β-Catenin Pathway Gene Expression.
β-Catenin expression decreased in A. m, A. h, DTX, and
A. h +DTX groups compared to control, but this decrease
was significant in A. h +DTX (IC50 + IC25) group.
FZD7 expression in A. m+DTX (IC50 + IC25) group
showed a significant decrease, but, in A. h +DTX
(IC50 + IC25) group, there was a significant increase. *e
expression of VEGF-a did not change significantly in any of
the groups.
*e expression of HIF-1α increased in A. h +DTX
(IC50 + IC10) group, but this increase was not significant.
*e combination treatment in A. m+DTX (IC50 + IC10)
and (IC50 + IC25) groups showed a significant down-
regulation in mRNA expression levels of HIF-1α compared
to the control. Data are shown in Figure 6.
4. Discussion
In this in vitro study, we investigated the combined effect of
A. m and A. h extracts with DTX-based chemotherapy on
the growth suppression of 4T1 cancer cell line. *e results of
this study with A. m and A. h extracts showed acceptable
IC50 values in inhibiting the growth of 4T1 cancer cells
including 57 µg/ml and 85 µg/ml, respectively.
(a) (b) (c) (d)
(e) (f ) (g) (h)
(i) (j) (k) (l)
Figure 5: AO/EB staining assay. (a) Negative control group: the circular nucleus distributed in the center of the cell. (b) DTX treated group:
nucleus showed granular appearance with yellow-green fluorescence by AO staining indicating apoptosis. (c) A.m (IC50): nucleus of the
cells showed orange fluorescence indicating late apoptosis. (d) A.h (IC50): the nucleus of cells showed yellow-green fluorescence and located
in bias. (e) A.m+DTX (IC50 + IC50) : yellow-green fluorescence was observed in the nucleus of cells. (f ) A.m+DTX (IC50 + IC10) :
apoptotic vesicles were observed out of the cells clearly. (g) A.m+DTX (IC25 + IC25) : the dominant red color by EB staining indicated
necrosis and they were disintegrating. (h) A.m+DTX (IC10 + IC10): late-stage apoptotic cells were detected with concentrated and
asymmetrically localized orange nuclear EB staining. (i) A.h +DTX (IC50 + IC50), (j) A.h +DTX (IC50 + IC10), and (l) A.h +DTX
(IC10 + IC10): apoptotic cells with nucleus showed yellow-green fluorescence and were located in one side of cells. (k) A.h +DTX
(IC25 + IC25): the dominant red color indicated necrosis. IC values were as follows: for A.m : IC10� 32 µg/ml, IC25� 40 µg/ml, and
IC50� 57 µg/ml; for A.h : IC10�10 µg/ml, IC25� 33 µg/ml, and IC50� 85 µg/ml; and for DTX : IC10� 0.4 µM, IC25� 3.5 µM, and
IC50�11 µM.
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A. m as a highly valuable plant has numerous sec-
ondary metabolites and flavonoids and has shown many
medicinal properties [29]. Over the past years, numerous
experimental studies have demonstrated that diethyl
ether and petroleum ether extracts of A. m had IC50
values of 114.7 µg/ml and 105.7 µg/ml against MCF7
human breast cancer cell line [16]. A. m extract showed
IC50s > 100 µg/ml against A549, MCF7, HepG2, HT-29,
and MDBK cell lines [30].
Synergy is a process in which the combined effect of the
participating elements is greater than the sum of their in-
dividual effects. Examining these interactions is important
because it may have advantages for treatment, even in
complex diseases such as cancer [31]; for example, ginseng
increases the cytotoxicity of docetaxel, cisplatin, and
doxorubicin [32].
In our study, A. m at concentrations below 100 µg/ml, in
combination with the DTX, showed a synergistic behavior
and reduced the IC50 value of DTX with a significant and
steep gradient. A. m at concentrations above 100 µg/ml alone
showed a higher suppression of cancer cell growth, so the
CompuSyn software did not offer synergy in comparison to
individual and combined modes. A. m extract also inhibited
the migration of 4T1 cells both alone and in combination
with DTX. Additionally, we found the increased percentages
of apoptotic cells in A. m+DTX (IC50 + IC25 and
IC50 + IC10) combinations compared to A. m extract alone,
which were close to the percentage of apoptosis caused by
DTX. In A. m+DTX (IC50 + IC10) group, apoptotic bodies
were also clearly seen. It appears that when the amount of
A. m extract in combination therapy is greater thanDTX, the






































































































































































































































































































Figure 6: Effect of DTX, A.m, and A.h extracts and A.m or A.h +DTX combination groups on expression levels of β-Catenin, FZD7, VEGF-
a, and HIF-1α genes accomplished by real-time PCR. Data are represented as the relative expression level compared to GAPDH on the basis
of Pfaffl method, presented as mean± SD. Significance was set at ∗P< 0.05. IC values were as follows: for A.m : IC10� 32 µg/ml,
IC25� 40 µg/ml, and IC50� 57 µg/ml; for A.h : IC10�10 µg/ml, IC25� 33 µg/ml, and IC50� 85 µg/ml; and for DTX : IC10� 0.4 µM,
IC25� 3.5 µM, and IC50�11 µM.
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(IC10 + IC10) combination group showed the least necrosis,
and when the amount of DTX increased, the necrosis also
was increased. *e A. m+DTX (IC50 + IC10 and
IC50 + IC25) combination groups also significantly reduced
the expression level of the HIF-1α gene. It seems that IC10 of
DTX in combination with IC50 of A. m was more effective
than IC25 of DTX. Also, A. m+DTX (IC50 + IC25) group
downregulated the expression of FZD7 gene. In other
studies, Lupeol from A. m extracts reduced mRNA ex-
pression level of p53, caspase-3, and bax genes inMCF-7 and
MDA-MB-231 cell lines; however, bcl-2 gene expression was
decreased [22].
Docetaxel is generally accepted as the chemotherapy agent
for patients with advanced breast cancer [7], but its clinical
efficacy can be compromised by serious related side effects. So,
controlling DTX therapy-related side effects may improve
clinical outcomes in patients undergoing chemotherapy.
Considering that A. m extract in combination with DTX
showed synergistic behavior in concentrations below 100µg/ml,
this combination may be inhibiting cancer cell growth in breast
cancer and reduce the side effects of chemotherapy. According
to previous reviewed information, A. m has got great scope for
phytochemical and pharmacological studies to prove its ther-
apeutic potential [19]. In combination with DTX, A. m in
concentrations below 100µg/ml can be a potential comple-
mentary therapeutic option in breast cancer.
A. h fruits, oil, and even leaves in traditional medicine
have been used for numerous treatments, but the efficacy of
the extract in breast cancer has not been studied. A. h,
though alone, had an acceptable IC50 against 4T1 cells but
showed a contradictory behavior in combination therapy. In
the combination of A. h with DTX, CI> 1 was obtained,
indicating antagonism. Although it was able to reduce the
IC50 value of DTX, it was, of course, less steep than that of
A. m. A. h +DTX (IC50 + IC10 and IC10 + IC10) combi-
nation groups induced apoptosis even more than DTX
alone, and A. h +DTX (IC50 + IC10) group presented 63.3%
apoptosis. *e gene expression analysis showed that
A. h +DTX (IC50 + IC25) significantly downregulated
β-Catenin. However, A. h +DTX (IC50 + IC25) increased
expression of FZD gene; this group showed the least apo-
ptosis compared to other groups. *e good potential of A. h
in inhibiting the migration of 4T1 cells and inducing apo-
ptosis was quantitatively and qualitatively evident. Since A. h
in combinationmode slowly reduced the IC50 value of DTX,
the synergistic behavior could be observed probably by
increasing the treatment duration or changing the con-
centrations. In fact, the concentrations or treatment time we
used for this study may not have been adequate or sufficient
to create a synergistic state for A. h.
5. Conclusion
Briefly, we investigated the combination effect of A. m and
A. h extracts with DTX for the first time. A. m and A. h
extracts inhibited the growth of 4T1 cancer cells. Having
definitive synergistic effect in concentrations below 100 µg/
ml, A. m extract can be a good alternative in combination
with DTX. Natural products are a huge source of diverse
elements in drug research. *ese types of studies help to
identify susceptible plants in this context and develop these
research studies. A. m and A. h extracts may have a good
potential for becoming drugs given their acceptable IC50s in
inhibiting the growth of 4T1 cancer cells. Nevertheless, it is
necessary to examine the effects of these medicinal plants
individually and in combination with DTX in animal model
and clinical trial.
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